IP Library Granted Patent US 9,957,246
Granted Patent B2
US 9,957,246 · App. 15/374,281 · Granted May 1, 2018

Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,957,246
App. No.
15/374,281
Granted
May 1, 2018
Kind
B2
Abstract

Described herein are Δ 9 -THC prodrugs, methods of making Δ 9 -THC prodrugs, formulations comprising Δ 9 -THC prodrugs and methods of using Δ 9 -THC. One embodiment described herein relates to the transdermal administration of a Δ 9 -THC prodrug for treating and preventing diseases and/or disorders.

Claims (21)

1. A composition comprising a compound selected from:

or combinations thereof.

2. A pharmaceutical composition comprising

a) a compound selected from:

or combinations thereof; and

b) a pharmaceutical excipient.

3. The pharmaceutical composition of claim 2 , wherein the pharmaceutical excipient is selected from the group consisting of propylene glycol, ethanol, diethylene glycol monoethyl ether, hydroxyethylcellose, and combinations thereof.

4. The pharmaceutical composition of claim 2 , wherein the pharmaceutical excipient comprises propylene glycol, ethanol, diethylene glycol monoethyl ether, and hydroxyethylcellose.

5. The pharmaceutical composition of claim 2 , wherein the pharmaceutical excipient consists essentially of propylene glycol, ethanol, diethylene glycol monoethyl ether, and hydroxyethylcellose.

6. A method of treating peripheral neuropathic pain or fibromyalgia in a subject comprising

administering a pharmaceutical composition, the pharmaceutical composition comprising:

a) a compound selected from:

 or combinations thereof; and

b) a pharmaceutical excipient;

and wherein the method treats peripheral neuropathic pain or fibromyalgia.

7. The method of treatment of claim 6 wherein the method treats peripheral neuropathic pain.

8. The method of treatment of claim 6 wherein the method treats fibromyalgia.

9. The method of claim 7 wherein the step of administering the pharmaceutical composition comprises administering the pharmaceutical composition transdermally.

10. The method of claim 8 wherein the step of administering the pharmaceutical composition comprises administering the pharmaceutical composition transdermally.

11. The pharmaceutical composition of claim 2 , further comprising a patch, wherein the compound and the pharmaceutical excipient are contained within the patch.

12. The method of claim 6 , wherein the pharmaceutical excipient is selected from the group consisting of propylene glycol, ethanol, diethylene glycol monoethyl ether, hydroxyethylcellose, and combinations thereof.

Assignments (6)
SUPPLEMENTAL CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded May 18, 2026
From: HARMONY BIOSCIENCES MANAGEMENT, INC. (F/K/A ZYNERBA PHARMACEUTICALS, INC.)
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 075642/0639 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2017
From: STINCHCOMB, AUDRA LYNN; GOLINSKI, MIROSLAW JERZY; HAMMELL, DANA CARMEL; HOWARD, JEFFREY LYNN
To: ALLTRANZ INC.
Reel/Frame 040930/0965 →
CONDITIONAL ASSIGNMENT Recorded Jan 10, 2017
From: ALLTRANZ INC.
To: KENTUCKY ECONOMIC DEVELOPMENT FINANCE AUTHORITY
Reel/Frame 040932/0423 →
RELEASE OF SECURITY INTEREST Recorded Jan 10, 2017
From: KENTUCKY ECONOMIC DEVELOPMENT FINANCE AUTHORITY
To: ZYNERBA PHARMACEUTICALS, INC.
Reel/Frame 040932/0906 →
CHANGE OF NAME Recorded Jan 10, 2017
From: ALLTRANZ INC.
To: ZYNERBA PHARMACEUTICALS, INC.
Reel/Frame 041313/0415 →
RELEASE OF SECURITY INTEREST Recorded Jan 10, 2017
From: KENTUCKY ECONOMIC DEVELOPMENT FINANCE AUTHORITY
To: ZYNERBA PHARMACEUTICALS, INC.
Reel/Frame 041313/0610 →